A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)
Study Identifier:
CLI-06001AA1-05
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Study Contact Information:
Recruiting
Study Details
Medical Condition
- Chronic Obstructive Pulmonary Disease
Study Drug
- Drug: CHF6001 1600µg
- Drug: CHF6001 3200µg
- Drug: Placebo
- Drug: Roflumilast
Date
Jul 2021 - Apr 2027
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 40+ years
Requirements Information
Healthy Volunteers
No
Protocol Summary
The purpose of this study is to evaluate the efficacy and the safety of two doses of CHF6001 (Tanimilast) as add-on to maintenance triple therapy in the target patient population.
Study Locations
Location
Status
Location
Chiesi Clinical Trial - Site 840635
Andalusia, Alabama, United States, 36420-5310
Status
Terminated
Location
Chiesi Clinical Trial - Site 840614
Foley, Alabama, United States, 36535-2248
Status
Recruiting
Location
Chiesi Clinical Trial - Site 840670
Guntersville, Alabama, United States, 35976-2206
Status
Recruiting
Location
Chiesi Clinical Trial - Site 840720
Mobile, Alabama, United States, 36608
Status
Recruiting
Location
Chiesi Clinical Trial - Site 840643
Saraland, Alabama, United States, 36571-3014
Status
Recruiting
Location
Chiesi Clinical Trial - Site 840638
Phoenix, Arizona, United States, 85018-5434
Status
Recruiting